Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure
Authors:
- Iffet CavdarICIffet Cavdar
- Lebriz UsluLULebriz Uslu
- Mohammad AbuqbeitahMAMohammad Abuqbeitah
- Mustafa DemirMDMustafa Demir
- 1 March 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (3) , 283-287
Abstract
Radioiodine therapy could be challenging in chronic renal failure patients requiring hemodialysis. The aim of this study was to establish the effects of hemodialysis on elimination of radioiodine from the body in thyroid carcinoma patients with end-stage chronic renal failure and to determine its effects on environmental radiation dose. Three end-stage chronic renal failure patients (four cases) diagnosed with differentiated thyroid carcinoma requiring radioiodine therapy were included in our study. Each patient was given 50-75 mCi (1850-2775 MBq) iodine-131 with 50% dose reduction. Dose rate measurement was performed at the 2nd, 24th, and 48th hour (immediately before and after hemodialysis) after radioiodine administration. The Geiger-Müller probe was held at 1 m distance at the level of the midpoint of the thorax for the dose rate measurement. The effective half-life of iodine-131 for three patients was found to be 44 h. In conclusion, the amount of radioiodine excreted per hemodialysis session was calculated to be 51.25%.Keywords
This publication has 14 references indexed in Scilit:
- Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysisNuclear Medicine Communications, 2014
- Hemodialysis in Patients Requiring 131I Treatment for Thyroid CarcinomaThe International Journal of Artificial Organs, 2013
- The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancerRadiation Protection Dosimetry, 2013
- The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid CancerThyroid®, 2009
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Guidelines for radioiodine therapy of differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerationsHormones, 2006
- Iodine-131 Treatment of Thyroid Papillary Carcinoma in Patients Undergoing Dialysis for Chronic Renal Failure: A Dosimetric MethodThyroid®, 2001
- Iodine-131 Ablation Therapy for a Patient Receiving Peritoneal DialysisClinical Nuclear Medicine, 2001
- Iodine Metabolism and Thyroid Physiology: Current ConceptsThyroid®, 1997